2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1529

The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Abstract Number: 1530

Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Abstract Number: 1531

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis
Abstract Number: 1532

Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study
Abstract Number: 1533

The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Abstract Number: 1534

Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Abstract Number: 1535

Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Abstract Number: 1536

A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Abstract Number: 1537

Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Abstract Number: 1538

The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Abstract Number: 1539

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Abstract Number: 1540

Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Abstract Number: 1541

Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis
Abstract Number: 1542

Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Abstract Number: 1543

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].